BioCentury
ARTICLE | Clinical News

OvaScience falls on IVF trial halt

September 12, 2013 12:25 AM UTC

OvaScience Inc. (NASDAQ:OVAS) fell $3.32 (23%) to $10.95 on Wednesday after the fertility company suspended enrollment of a U.S. trial evaluating Augment, which is intended to increase the success of in vitro fertilization (IVF). OvaScience suspended the trial after receiving a letter from FDA advising the company to submit an IND. According to the company, FDA said there "appears to be more than minimal manipulation" with Augment, a process that involves isolating mitochondria from a woman's egg precursor cells and injecting them into her egg along with a sperm cell to improve the success rate of IVF. ...